ANI Pharmaceuticals
ANIP
ANIP
170 hedge funds and large institutions have $319M invested in ANI Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 52 increasing their positions, 64 reducing their positions, and 22 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding in top 10
Funds holding in top 10: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
less funds holding
Funds holding: →
3.7% less ownership
Funds ownership: 63.45% → 59.76% (-3.7%)
19% less repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 64
25% less capital invested
Capital invested by funds: $424M → $319M (-$105M)
Holders
170
Holding in Top 10
1
Calls
$1.55M
Puts
$1.11M
Top Buyers
| 1 | +$8.26M | |
| 2 | +$3.39M | |
| 3 | +$1.7M | |
| 4 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$1.67M |
| 5 |
PFC
Phocas Financial Corp
Alameda,
California
|
+$1.47M |
Top Sellers
| 1 | -$10.4M | |
| 2 | -$9.28M | |
| 3 | -$4.14M | |
| 4 |
Invesco
Atlanta,
Georgia
|
-$2.68M |
| 5 |
Goldman Sachs
New York
|
-$2.39M |